Related Experiment Videos
Apolipoprotein C-III gene variation and dyslipidaemia
1Department of Medicine, University College London Medical School, UK.
Current Opinion in Lipidology
|June 1, 1997
Summary
The Ssti gene variant strongly links to high triglyceride levels and heart disease. Molecular mechanisms behind this association remain unclear, as promoter variations don't fully explain the Ssti effect.
Area of Science:
- Genetics
- Cardiovascular Disease
- Metabolic Disorders
Background:
- The apolipoprotein C-III (APOC3) gene cluster is crucial in lipid metabolism.
- The Ssti polymorphism in APOC3's 3' untranslated region is linked to elevated triglycerides and coronary artery disease.
- Existing explanations, like promoter variations, don't fully account for the Ssti polymorphism's impact.
Purpose of the Study:
- To investigate the molecular mechanisms underlying the association between the Ssti polymorphism and altered lipid levels.
- To elucidate how the Ssti variant influences apolipoprotein C-III gene expression and its downstream effects on triglyceride levels.
Main Methods:
- Analysis of the apolipoprotein A-I-C-III-A-IV gene cluster.
- Genotyping for the Ssti polymorphism.
- Assessment of plasma triglyceride levels.
- Investigation of potential regulatory elements in the apolipoprotein C-III gene.
Main Results:
- The Ssti polymorphism is a significant genetic factor associated with increased plasma triglyceride levels.
- The Ssti variant's effect on triglyceride levels is consistently observed.
- The precise molecular mechanisms driving this association require further elucidation beyond promoter activity.
Conclusions:
- The Ssti polymorphism in the apolipoprotein C-III gene is a key genetic determinant of plasma triglyceride levels.
- Understanding the molecular basis of the Ssti effect is critical for addressing associated cardiovascular risks.
- Further research is needed to fully identify the mechanisms linking Ssti to dyslipidemia.